Skip to main content

Table 1 Characteristics of the 77 patients of tigecycline-treated pneumonia involving multidrugresistant Acinetobacter baumannii (MDRAB)

From: Clinical experience with tigecycline in the treatment of hospital-acquired pneumonia caused by multidrug resistant Acinetobacter baumannii

Characteristics values
Demographic parameters
 Age, mean ± SD, years 62.1 ± 17.0
 Male/Female 52/25
Comorbidities
 Hepatic dysfunction 2 (2.6%)
 Renal insufficiency 7 (9.1%)
 Chronic pulmonary disease 24 (31.2%)
 Heart disease 14 (18.2%)
 Hypertension 17 (22.1%)
 Diabetes mellitus 6 (7.8%)
 Immune compromise 5 (6.5%)
 multiple organ failure 3 (3.9%)
 Malignancy 8 (10.4%)
 Surgery 16 (20.8%)
Clinical conditions
 CURB65 score, mean ± SD 2.0 ± 1.0
 Mechanical ventilation 48 (62.3%)
Susceptibility tests of initial airway MDRAB isolates
 With sensitive to tigecycline 42 (54.5%)
 With sensitive to sulbactam 7 (9.1%)
Tigecycline treatment
 Duration, mean ± SD, days 11.69 ± 6.11
 Combination therapy 71 (92.2%)
  With sulbactam 64 (90.1%)
  With carbapenems 4 (5.6%)
  With amikacin 1 (1.4%)
  With fluoroquinolones 4 (5.6%)
Delayed tigecycline treatment 21 (27.3%)
  1. Abbreviations: SD standard deviation